Targeting metabolism in pancreatic cancer
Mené sur 20 patients atteints d'un cancer métastatique du pancréas, cet essai de phase I évalue la dose maximale tolérée d'un composé appelé CPI-613 et dispensé en combinaison avec une chimiothérapie de type FOLFIRINOX modifié (oxaliplatine, leucovorine, irinotécan, fluorouracile)
Targeting altered metabolism in cancer is an intriguing concept. The Warburg effect—the observation that cancer cells use energy from glucose even when there is enough oxygen (aerobic glycolysis)—has been almost forgotten for a long time. However, recently, studies on cancer cell-specific metabolism have uncovered many of the biochemical mechanisms underlying this shift in energy provision.1 Several drugs have been developed that target altered metabolic pathways in cancer.2 Among these, CPI-613—an agent that inhibits cancer-specific mitochondrial energy metabolism—has recently gained attention and has been shown to be well tolerated and effective in various cancers.
The Lancet Oncology , commentaire, 2016